# A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

> **NCT06583486** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Chongqing Claruvis Pharmaceutical Co., Ltd.** · enrollment: 488 (actual)

## Conditions studied

- Moderate to Severe Glabellar Lines

## Interventions

- **BIOLOGICAL:** Rcombinant botulinum neurotoxin type A for injection (YY001)

## Key facts

- **NCT ID:** NCT06583486
- **Lead sponsor:** Chongqing Claruvis Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-19
- **Primary completion:** 2025-08-20
- **Final completion:** 2025-08-20
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2024-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06583486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06583486, "A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06583486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*